Patent Settlements Blocking Authorized Generics May Get Supreme Court Review
GlaxoSmithKline and Teva hope that lower court disagreements, if not exactly a circuit split, will be enough to get high court to revisit its Actavis decision.
GlaxoSmithKline and Teva hope that lower court disagreements, if not exactly a circuit split, will be enough to get high court to revisit its Actavis decision.